Emi Takashita et al.: Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2, in: New England Journal of Medicine Vol. 386, Issue 15 (April 14, 2022) pp. 1475-1477, online in: https://doi.org/10.1056/NEJMc2201933. In their letter to the editor, the authors report on their study looking at the efficacy of monoclonal antibodies against the omicron subvariants. They conclude that both etesevimab and bamlanivimab have lost neutralizing activity against the omicron subvariant BA.2. Imdevimab, which had no neutralizing activity against BA.1, however, has neutralizing activity against BA.2. Casirivimab inhibited BA.2 but not BA.1 or BA.1.1. Tixagevimab and cilgavimab neutralized BA. 2 with […]
Daily archives: 25. July 2022
1 post